Compare Inovio Pharmaceuticals Inc (INO) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs iShares Silver Trust — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while iShares Silver Trust trades at $55.04 (market cap $29.02B). The key difference: iShares Silver Trust is far larger — about 258.7× Inovio Pharmaceuticals Inc's market cap, and iShares Silver Trust is more actively traded (16,510,334 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and iShares Silver Trust for 89 Days on average.
| INO | SLV | |
|---|---|---|
Market Cap | $112.19M | $29.02B |
Volume | 3,201,278 | 16,510,334 |
Sector | Health | — |
52-Week High | $2.65 | $105.57 |
52-Week Low | $0.66 | $42.40 |
Typical Hold Time | 43 Days | 89 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
SLV trades at $54.85, up 1.91% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows minimal operational activity with $0 revenue and $2.17M net income in 2024, while assets surged to $13.4B from previous years. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious due to bearish technicals and macroeconomic pressures on precious metals. Investment opportunity exists for contrarian buyers given oversold conditions, but risks include continued Fed tightening and dollar strength. Silver's dual role as monetary and industrial metal adds volatility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
